Loading
Delcath Systems, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Pennell Sandra, was filed 06 Mar 2026.
Delcath Systems, Inc.: what insiders have been doing
This page follows insider dealings at Delcath Systems, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 4 insiders have disclosed 6 filings since 22 October 2025.
Every open-market trade in the period is a purchase: 4 purchases worth €247k, from 3 insiders, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 finance chief, 1 senior executive and 1 chief executive among the declarants. One trade stands out by size: a purchase of €85k from Michel Gerard J, disclosed on 3 March 2026.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 232 days ago, on 6 March 2026. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade.
Compared with its exchange (3,169 companies, median 24 filings), a count of 6 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 60 purchases and no sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 85.2 m USD and net income at 2.7 m USD.
In the same sector, recent insider purchases at UCB also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
127
Thresholds
n/a
Buy Volume
€8M
60 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGerard J. Michel2 buys
John Richard Sylvester1 buy
Sandra Pennell1 buy
Since the insiders bought
- +17.0%Entry US$9.12 · Close at T+90 US$10.67
- +59.3%Entry US$9.23 · Close 21 Oct 2026 US$14.70
- +52.5%Entry US$9.64 · Close 21 Oct 2026 US$14.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,379 of 26,284 companies
53.0
score / 100
Value48
Quality59
FCF yld4.1%
Earn yld0.5%
EV/EBITDA·
ROE0.5%
Gross mgn86%
Net mgn3.2%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.76
Analyst consensus
5 analysts1.20/5
US$21.00Target US$24.00(+63%)US$32.00
Income statement
RevenueUS$85.2M
Gross profitUS$73.4M86% margin
EBITDAUS$1M1% margin
Net incomeUS$2.7M0.6% margin
Valuation
PER (trailing)1476.0x
PER (forward)328.0x
P/Book4.2x
Beta0.60
Balance sheet & cash
Market capUS$512.2M
Total debtUS$936k
Free Cash FlowUS$21M
Debt / Equity2%
Profitability & ownership
ROE0.5%
ROA-0.9%
% insiders8.1%
% institutions52.0%
Last declaration on 14 October 2026
Declarations127 total
27,502 shares0Common StockSEC:0001622627-26-000026:1
3,627 shares0Common StockSEC:0001622627-26-000026:0
5,533 shares@ US$9.04100.0% of flowCommon StockSEC:0001824817-26-000006:0
Canonical exit: 4 Jun 2026 (T+90)
11,200 shares@ US$8.956220.5% of flowCommon StockSEC:0001235644-26-000007:0
Canonical exit: 31 May 2026 (T+90)
4,386 shares@ US$8.89100.0% of flowCommon StockSEC:0001784561-25-000005:0
Canonical exit: 19 Feb 2026 (T+90)
11,500 shares@ US$8.52620.4% of flowCommon StockSEC:0001235644-25-000004:0
Canonical exit: 9 Feb 2026 (T+90)
42,000 shares@ US$4.78100.0% of flowCommon StockSEC:0001415889-25-017260:0
400,000 shares@ US$10.0058.1% of flowCommon sharesSEC:0001622627-25-000019:0
400,000 shares@ US$10.0056.9% of flowCommon sharesSEC:0001622627-25-000018:0
400,000 shares@ US$10.0058.6% of flowCommon sharesSEC:0001622627-25-000020:0
250,000 shares@ US$10.0039.5% of flowCommon sharesSEC:0001623082-24-000006:0
250,000 shares@ US$10.0038.6% of flowCommon sharesSEC:0001622627-24-000065:0
250,000 shares@ US$10.0039.8% of flowCommon sharesSEC:0001811824-24-000006:0
16,666 shares@ US$6.0010.0% of flowCommon StockSEC:0001415889-24-025566:0
991,615 shares0Common SharesSEC:0001622627-24-000029:1
991,615 shares0Common SharesSEC:0001622627-24-000030:1
991,615 shares0Common SharesSEC:0001811824-24-000003:1
991,615 shares0Common SharesSEC:0001623082-24-000004:1
619,946 shares@ US$6,199.46Common SharesSEC:0001623082-24-000003:1
991,615 shares0Common SharesSEC:0001811824-24-000002:1
991,615 shares0Common SharesSEC:0001623082-24-000003:0
619,946 shares@ US$0.010.1% of flowCommon SharesSEC:0001622627-24-000030:0
619,946 shares@ €5,824.26999.8% of flowCommon SharesSEC:0001811824-24-000002:0
619,946 shares@ US$0.010.1% of flowCommon SharesSEC:0001811824-24-000003:0
619,946 shares@ US$0.010.1% of flowCommon SharesSEC:0001623082-24-000004:0
25 of 127 declarations
About Delcath Systems, Inc.
Delcath Systems, Inc. is a U.S.-based oncology-focused healthcare company listed on the Nasdaq Capital Market under the ticker DCTH, in the United States. Founded in 1988, the company was built around a highly specialized mission: developing liver-directed drug delivery systems designed to deliver high-dose chemotherapy to the liver while reducing systemic exposure. Its operating headquarters are in Queensbury, New York, giving Delcath the profile of a U.S. healthcare small cap with a strong clinical and regulatory overlay. ([investors.delcath.com](https://investors.delcath.com/ir-resources/faqs?utm_source=openai))
Delcath’s business is centered on two commercial platforms. In the U.S., the flagship product is HEPZATO KIT, a drug/device combination product used in the treatment of primary and metastatic liver cancers, especially where disease is liver-dominant. In Europe, the company markets CHEMOSAT, the device-based version of its hepatic delivery system, which is used at specialized medical centers for liver cancer treatment. This creates a business model that combines specialty pharma, medical devices, and clinical center activation and support. ([delcath.com](https://delcath.com/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Delcath occupies a narrow but differentiated niche. It is not a broad diversified pharma group; instead, it is a focused interventional oncology player addressing a specific clinical need: regional hepatic chemotherapy delivery. That focus can be an advantage because it creates clear therapeutic positioning and a potentially defensible technology platform, but it also means the business is highly dependent on physician adoption, reimbursement, regulatory execution, and the pace of center activation. The FDA approval of HEPZATO and the establishment of a product-specific reimbursement code are important commercial milestones that support adoption and monetization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/872912/000162828026022951/dcth202510kforproxy.pdf?utm_source=openai))
Recent developments point to meaningful momentum. In 2025, Delcath reported strong revenue growth driven primarily by HEPZATO KIT, along with improving gross margins and an expanding treatment-center footprint. The company also advanced its clinical franchise: CHOPIN data were published in The Lancet Oncology in 2026, adding external validation to the platform’s clinical rationale. For investors, Delcath remains a specialized U.S. Nasdaq healthcare name with high operating leverage, where the key watch items are reimbursement durability, commercial uptake, clinical expansion, and continued execution in the U.S. and Europe. ([investors.delcath.com](https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
